Ubs Group Ag Cocrystal Pharma, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$0.27 - $3.6 $1,127 - $15,033
4,176 Added 296.59%
5,584 $2,000
Q2 2022

Aug 10, 2022
SELL
$0.38 - $0.55 $6,372 - $9,222
-16,769 Reduced 92.25%
1,408 $1,000
Q1 2022

May 16, 2022
SELL
$0.48 - $0.71 $8,205 - $12,136
-17,094 Reduced 48.46%
18,177 $10,000
Q4 2021

Feb 14, 2022
BUY
$0.65 - $1.02 $15,127 - $23,738
23,273 Added 193.97%
35,271 $23,000
Q3 2021

Nov 15, 2021
BUY
$1.01 - $1.25 $1,800 - $2,228
1,783 Added 17.45%
11,998 $13,000
Q2 2021

Aug 13, 2021
BUY
$1.08 - $2.14 $4,456 - $8,829
4,126 Added 67.76%
10,215 $13,000
Q1 2021

May 12, 2021
BUY
$1.3 - $2.35 $7,915 - $14,309
6,089 New
6,089 $8,000
Q4 2020

Feb 11, 2021
SELL
$0.8 - $2.16 $273 - $738
-342 Closed
0 $0
Q3 2020

Nov 12, 2020
SELL
$0.86 - $2.36 $14,615 - $40,108
-16,995 Reduced 98.03%
342 $0
Q2 2020

Jul 31, 2020
BUY
$0.7 - $1.58 $4,295 - $9,696
6,137 Added 54.79%
17,337 $26,000
Q1 2020

May 01, 2020
BUY
$0.48 - $2.19 $5,330 - $24,322
11,106 Added 11814.89%
11,200 $8,000
Q4 2019

Feb 14, 2020
BUY
$0.39 - $2.05 $36 - $192
94 New
94 $0
Q3 2019

Nov 14, 2019
SELL
$1.69 - $2.88 $657 - $1,120
-389 Closed
0 $0
Q2 2019

Aug 14, 2019
SELL
$2.06 - $2.75 $3,106 - $4,147
-1,508 Reduced 79.49%
389 $1,000
Q1 2019

May 14, 2019
BUY
$2.65 - $4.14 $5,027 - $7,853
1,897 New
1,897 $5,000
Q4 2018

Feb 14, 2019
SELL
$1.6 - $3.68 $6,600 - $15,180
-4,125 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$2.3 - $4.95 $9,487 - $20,418
4,125 New
4,125 $10,000
Q2 2018

Aug 14, 2018
SELL
$1.79 - $6.25 $4,650 - $16,237
-2,598 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$3.9 - $6.9 $10,132 - $17,926
2,598 New
2,598 $15,000

About Cocrystal Pharma, Inc.

COCP Quotes by TradingView
  • Ticker COCP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,122,420
  • Market Cap $21.3M
  • Description
  • Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company ...
More about COCP
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email